Tesofensine
Also known as: Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated as an anti-obesity drug. It produces appetite suppression and notable weight loss in clinical trials. Note: Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide, but is sold alongside metabolic research compounds.
Last updated
Mechanism of Action
Tesofensine inhibits the presynaptic reuptake of dopamine, norepinephrine, and serotonin, raising synaptic concentrations of all three monoamines. The resulting enhancement of dopaminergic and noradrenergic tone in hypothalamic and reward circuits suppresses appetite and may increase resting energy expenditure. Its serotonergic and noradrenergic actions also contribute to satiety signaling and reduced food intake.
- Half-life
- Approximately 220 hours (around 9 days)
- Administration Routes
- oral
- Research Status
- Research Chemical
Reported Benefits
- Significant appetite suppression
- Substantial weight loss in clinical trials
- May increase energy expenditure
- Potential improvements in mood and alertness
- Investigated for metabolic and obesity-related endpoints
Potential Side Effects
- Increased heart rate and blood pressure
- Insomnia and sleep disturbance
- Dry mouth
- Nausea and gastrointestinal upset
- Mood changes, anxiety, or irritability
Common Dosing
Clinical obesity trials evaluated oral doses around 0.25 to 1.0 mg once daily; the long half-life means levels accumulate over time. For research use only and not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Cardiovascular disease, hypertension, or arrhythmias
- Concurrent use of MAO inhibitors or other serotonergic agents
- History of psychiatric disorders such as severe anxiety or mania
Semaglutide
A long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Among the most effective approved weight-loss therapies.
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
AOD-9604
A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat-loss effects without the broader growth-promoting actions of full GH.
- View
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13
2009
- View
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
2008
Note: The Lancet published an expression of concern about this paper in 2013.
- View
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease
2008
- View
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
2010
- View
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
2022